MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings
Bears are Losing Control Over Stem (STEM), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Stem (STEM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Plant Stem Cell Market Review 2020-2024 and Forecast 2025-2030: Unilever, Renature Skin Care, and Other Key Players Leading the Industry
Key market opportunities in the Plant Stem Cell Market include leveraging the consumer shift toward natural and sustainable products, especially in cosmetics and healthcare, driving demand with biotechnological advancements, and capitalizing on regenerative medicine investments and eco-conscious trends for sustainable competitive advantages. Key market opportunities in the Plant Stem Cell Market include leveraging the consumer shift toward natural and sustainable products, especially in cosmetics and healthcare, driving demand with biotechnological advancements, and capitalizing on regenerative medicine investments and eco-conscious trends for sustainable competitive advantages.
Stem Jumps 32% in a Month: Should You Add the Stock to Your Portfolio?
STEM's performance shines with a record cash flow, margin expansion and software-led growth, setting the stage for a profitable 2025.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Stem (STEM)
Stem (STEM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Stem, Inc. (STEM) Reports Q1 Loss, Tops Revenue Estimates
Stem, Inc. (STEM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.46 per share a year ago.
Stem, Inc. (STEM) Q1 2025 Earnings Call Transcript
Stem, Inc. (NYSE:STEM ) Q1 2025 Earnings Conference Call April 29, 2025 5:00 PM ET Company Participants Ted Durbin - Head, IR Arun Narayanan - CEO Doran Hole - CFO and EVP Conference Call Participants Justin Clare - ROTH Capital Partners Thomas Boyes - TD Cowen Dylan Nassano - Wolfe Research Operator Greetings, and welcome to the Stem, Inc. First Quarter 2025 Results Conference Call. At this time, all participants are in listen-only mode.
Stem to Report Q1 Earnings: What's in the Cards for the Stock?
STEM's first-quarter 2025 performance is expected to have benefited from PowerTrack momentum and cost cuts amid continued weakness in hardware sales.
Stem Announces First Quarter 2025 Results Conference Call
SAN FRANCISCO--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader in artificial intelligence (AI)-driven clean energy solutions and services, will hold a conference call on Tues., April 29, 2025 to discuss its results for the first quarter ended March 31. The conference call is scheduled to begin at 5 p.m. ET. A press release regarding the results will be issued at approximately 4:05 p.m. ET. The conference call may be accessed via a live webcast on a listen-only basis at Click Here
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2024. FY 2024 Financial Highlights: Revenues increased to $9.09 million in 2024, an increase of 17% compared to $7.79 million in 2023.
Stem Drops 13% in a Month: Are the Shares Worth Buying on the Dip?
STEM drives growth with AI-powered energy solutions, expanding global reach, high-margin software and a strong focus on cost optimization for 2025.
Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine.
